September 1, 2008 - Diamyd Medical (Pink Sheets:DMYDY)(STO:DIAMB) reports that its Nerve Targeting Drug Delivery System (NTDDS) expressing enkephalin, is effective in preclinical models of diabetes pain - Dr. David Fink, published in the scientific journal “Journal of Neuroscience” that Diamyd Medical’s proprietary NTDDS platform, expressing enkephalin, effectively relieves pain due to diabetes in animals. The NTDDS platform allows focal delivery of the human enkephalin gene directly to nerves experiencing pain. ”These new data indicate that not only is the NTDDS platform with enkephalin effective at reducing pain, it reverses the root cause of diabetes related pain. This means that the approach is not just pain relief, but local pain prevention”, says Darren Wolfe, President of Diamyd Inc.
Elisabeth Lindner, President and CEO of Diamyd Medical, states “We have positioned Diamyd Medical as a diabetes company. These exciting results give us the opportunity to expand our product portfolio to include a third diabetes related product, NP2”... Diamyd's Press Release -
